LOWELL, Mass., Dec. 20, 2018 /PRNewswire/ -- Alcyone Lifesciences, Inc., a leader in breakthrough technologies to treat
"We are delighted to announce this strategic collaboration with the Roche neuroscience group, which represents significant potential for patients with neurological conditions," stated PJ Anand, Alcyone's chief executive officer. "We believe our intelligent intrathecal delivery platform will help to bring transformative disease-modifying therapies to help patients with severe central nervous system (CNS) conditions. This collaboration is another clear validation that Alcyone addresses a significant unmet need within biopharma's therapy development pipelines."
About Alcyone Lifesciences, Inc.Alcyone Lifesciences, based in Lowell, Massachusetts, is a privately-held biotechnology company passionately committed to applying engineering and science in the field of neurosciences and oncology to enable transformative therapies. For more information, please visit www.alcyonels.com
ContactAlcyone Lifesciences, Inc.PJ AnandChief Executive Officer978email@example.com
View original content:http://www.prnewswire.com/news-releases/alcyone-lifesciences-announces-broad-strategic-collaboration-with-roche-in-the-field-of-intrathecal-therapies-300769130.html
SOURCE Alcyone Lifesciences, Inc.
Subscribe to our Free Newsletters!